CMR Surgical has completed a financing round of more than $200m, combining equity and debt capital to expedite the commercialisation of its Versius Surgical Robotic System, particularly focusing on the US market.
Through these funds, the company also aims to bolster its growth strategy.
Go deeper with GlobalData
The financing round is supported by all current investors and includes a debt investment from alternative asset manager Trinity Capital, which has pledged up to $68.75m in growth capital to the company as part of this current financing initiative.
The funds will also support ongoing innovation and product development, including the introduction of the enhanced Versius Plus.
Armentum Partners served as the company’s financial adviser for the debt financing of the funding round.
Deployed in more than 30,000 surgeries across over 30 nations so far, the Versius system aims to enhance surgical procedures. It received de novo marketing clearance from the US Food and Drug Administration (FDA) last year for cholecystectomy procedures in adults aged over 22.
Versius “biomimics” the arm of the human, offering surgeons dexterity and precision with fully wristed, small instruments.
CMR is anticipating the broadening of its clinical footprint through two ongoing trials, a multi-centre prospective study of Versius in paediatric surgery and a transoral robotic surgery (TORS) study, showcasing the system’s “versatility” in surgical applications.
CMR Surgical CEO Massimiliano Colella said: “We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the US, while continuing to penetrate deeper into existing markets.
“I would like to give thanks to our chief financial officer, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic-assisted surgery accessible to all patients who need it whilst accelerating future product development.”
With its headquarters in the UK, CMR is collaborating with surgeons and hospitals to make robotic minimal-access surgery widely “affordable” and “accessible”.
